107166-90-5

Upstream product

• 931-63-5 2-methoxypyrimidine 
• 292638-85-8 acrylic acid methyl ester 
• 14001-66-2 5-bromo-2-methoxypyrimidine 
• 101803-06-9 5-iodo-2-methoxypyrimidine 

Downstream Products

• 1380427-01-9 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]oxy}-1-methyl-5-{[2-(methyloxy)-5-pyrimidinyl]methyl}-4(1H)-pyrimidinone 
• 1380427-00-8 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]oxy}-5-{[2-(methyloxy)-5-pyrimidinyl]methyl}-4(1H)-pyrimidinone 
• 1380428-67-0 2-{[2-(3-fluoro-4-{[6-(trifluoromethyl)-2-pyridinyl]oxy}phenyl)ethyl]oxy}-5-{[2-(methyloxy)-5-pyrimidinyl]methyl}-4(1H)-pyrimidinone 
• 221549-90-2 C₂₂H₂₀N₄O₅ 
• 173088-58-9 (E)-p-nitrophenyl 3-(2-methoxy-5-pyrimidinyl)acrylate 

Relevant academic research and scientific papers

A Convenient Synthesis of Methyl (E)-β-Pyrimidinylacrylates

A convenient synthesis of methyl (E)-β-pyrimidinylacrylates 5 is described. 5-Halopyrimidines react smoothly with methyl acrylate in the presence of palladium diacetate-triphenylphosphine complex in triethylamine to afford methyl (E)-β-pyrimidinylacrylates in satisfactory yields.Using this method an improved preparation of (E)-β-(2,4-dioxo-6-methyl-1,2,3,4-tetrahydropyrimidin-5-yl)acrylic acid is reported.

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).

New water-soluble duocarmycin derivatives: Synthesis and antitumor activity of A-ring pyrrole compounds bearing β-heteroarylacryloyl groups

A series of A-ring pyrrole compounds of duocarmycin bearing 4'-methoxy- β-heteroarylacryloyl groups were synthesized and evaluated for in vitro anticellular activity against HeLa S3 cells and in vivo antitumor activity against murine sarcoma 18

DC-89 derivatives

Provided are DC-89 derivatives represented by the formula: STR1 wherein X represents Cl or Br, R represents hydrogen or COR1, and W represents STR2 and pharmaceutically acceptable salts thereof. The compounds of the present invention have excellent anti-tumor activity and are useful as anti-tumor agents.